Article
ASH: Allogene's off-the-shelf CAR-T posts 60% response rate in fiercely competitive BCMA field
Rating:
0.0
Views:
31
Likes:
1
Library:
1
Allogene Therapeutics has linked its off-the-shelf anti-BCMA CAR-T cell therapy to a 60% response rate in a phase 1 trial. The candidate is up against autologous cell therapies that have set the efficacy bar high, but Allogene has off-the-shelf advantages and levers to pull to further improve outcomes.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value